Literature DB >> 11036044

Protection against lipopolysaccharide-induced death by fluoroquinolones.

A A Khan1, T R Slifer, F G Araujo, Y Suzuki, J S Remington.   

Abstract

Because fluoroquinolones have an immunomodulatory effect on cytokine production by lipopolysaccharide (LPS)-treated human monocytes, we examined the effect of fluoroquinolones on the survival of mice injected with a lethal dose of LPS. Trovafloxacin (100 mg/kg), ciprofloxacin (250 mg/kg), and tosufloxacin (100 mg/kg) protected 75% (P = 0.0001), 25% (P = 0.002), and 50% (P = 0.002), respectively, of mice against death. The fluoroquinolones significantly reduced serum levels of interleukin-6 and tumor necrosis factor alpha in LPS-treated mice. The protective effects of fluoroquinolones in LPS-induced shock in mice may also occur in humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036044      PMCID: PMC101624          DOI: 10.1128/AAC.44.11.3169-3173.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure.

Authors:  B O Anderson; D D Bensard; A H Harken
Journal:  Surg Gynecol Obstet       Date:  1991-05

Review 2.  Immunological aspects of new quinolones.

Authors:  I Shalit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 3.  Tumor necrosis, cachexia, shock, and inflammation: a common mediator.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

4.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.

Authors:  R C Bone; C J Fisher; T P Clemmer; G J Slotman; C A Metz; R A Balk
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

Review 5.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

6.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

7.  A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.

Authors:  R L Greenman; R M Schein; M A Martin; R P Wenzel; N R MacIntyre; G Emmanuel; H Chmel; R B Kohler; M McCarthy; J Plouffe
Journal:  JAMA       Date:  1991-08-28       Impact factor: 56.272

8.  Ciprofloxacin treatment in vivo increases the ex vivo capacity of lipopolysaccharide-stimulated human monocytes to produce IL-1, IL-6 and tumour necrosis factor-alpha.

Authors:  S Bailly; M Fay; B Ferrua; M A Gougerot-Pocidalo
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

9.  Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity.

Authors:  B Gårdlund; J Sjölin; A Nilsson; M Roll; C J Wickerts; B Wretlind
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

10.  Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention.

Authors:  L D Butler; N K Layman; R L Cain; P E Riedl; K M Mohler; J L Bobbitt; R Belagajie; J Sharp; A M Bendele
Journal:  Clin Immunol Immunopathol       Date:  1989-12
View more
  13 in total

1.  Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever.

Authors:  M Hussein Gasem; Monique Keuter; Wil M V Dolmans; Johanna Van Der Ven-Jongekrijg; Robert Djokomoeljanto; Jos W M Van Der Meer
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Comparative therapeutic effect of steroidal and non-steroidal anti-inflammatory drugs on pro-inflammatory cytokine production in water buffalo calves (Bubalus bubalis) naturally infected with bronchopneumonia: a randomized clinical trial.

Authors:  Mohamed Abdo Rizk; Motamed Elsayed Mahmoud; Shimaa Abd El-Salam El-Sayed; Doaa Salman
Journal:  Trop Anim Health Prod       Date:  2017-08-22       Impact factor: 1.559

3.  Potent Antiedematous and Protective Effects of Ciprofloxacin in Pulmonary Ricinosis.

Authors:  Yoav Gal; Anita Sapoznikov; Reut Falach; Sharon Ehrlich; Moshe Aftalion; Tamar Sabo; Chanoch Kronman
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 4.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 5.  Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis.

Authors:  Roland Nau; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Evaluation of the effectiveness of topical ciprofloxacin and prednisolone in the prevention of myringosclerosis.

Authors:  Necmi Arslan; Davut Tepe; Eren Taştan; Munir Demirci; Muzaffer Caydere; Huseyin Ustun; Haldun Oguz
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-12-25       Impact factor: 2.503

7.  Lack of interaction of fluoroquinolones with lipopolysaccharides.

Authors:  B Lindner; A Wiese; K Brandenburg; U Seydel; A Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

8.  Inhibition of secretion of interleukin-1alpha and tumor necrosis factor alpha by the ketolide antibiotic telithromycin.

Authors:  Fausto G Araujo; Teri L Slifer; Jack S Remington
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria.

Authors:  C A Gogos; A Skoutelis; A Lekkou; E Drosou; I Starakis; M N Marangos; H P Bassaris
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  Clindamycin modulates inflammatory-cytokine induction in lipopolysaccharide-stimulated mouse peritoneal macrophages.

Authors:  Tetsuji Nakano; Kazufumi Hiramatsu; Kenji Kishi; Norio Hirata; Jun-Ichi Kadota; Masaru Nasu
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.